Podcasts about Bayer

In this inspiring interview, Kimberly speaks with Jon Gordon who shares his personal journey through adversity, the power of positive habits, and practical strategies for living a fulfilled, purpose-driven life. Discover how small daily actions like gratitude walks, self-encouragement, and heart coherence can transform your mindset and overall well-being.Chapters00:00 Jon Gordon's Journey to Positivity02:48 The Power of Gratitude and Walking06:07 The Importance of Self-Talk09:02 Navigating Toxic Positivity11:58 Heart Coherence and Emotional Healing15:04 Creating Personal Boundaries17:57 The Role of Prayer in Daily Life21:02 Overcoming Fear and Building Courage23:56 Empowering Others Through Encouragement26:54 The Impact of Love on Fear29:52 Implementing Positive HabitsSponsors: LMNTOFFER: Right now, for my listeners LMNT is offering a free sample pack with any LMNT drink mix purchase at DrinkLMNT.com/FEELGOOD. That's 8 single serving packets FREE with any LMNT any LMNT drink mix purchase. This deal is only available through my link so. Also try the new LMNT Sparkling — a bold, 16-ounce can of sparkling electrolyte water.USE LINK: DrinkLMNT.com/FEELGOODBIRCH BEDS: OFFER: Go to BirchLiving.com/feelgood for 25% off Luxe Mattresses, 30% off Elite Mattresses and 20% off Site wide.USE LINK: BirchLiving.com/feelgoodJon Gordon Resources: Book: THE POWER OF POSITIVE HABITS: Proven Strategies to Exponentially Grow You Website: jongordon.com Social: Instagram: @jongordon11 Facebook: @jongordon X: @JonGordon11 Bio: Jon Gordon's best-selling books and talks have inspired readers and audiences around the world. His principles have been put to the test by numerous Fortune 500 companies, professional and college sports teams, school districts, hospitals, and non-profits. He is the author of 32 books including 18 best sellers and 5 children's books. His books include the timeless classic The Energy Bus which has sold over 3 million copies, The Carpenter which was a top 5 business book of the year, Training Camp, The Power of Positive Leadership, The Power of a Positive Team, The One Truth and his latest release The 7 Commitments of a Great Team. Jon and his tips have been featured on The Today Show, CNN, CNBC, The Golf Channel, Fox and Friends and in numerous magazines and newspapers. His clients include The Los Angeles Dodgers, In-N-Out Burger, The Los Angeles Rams, Campbell Soup, Dell, Publix, Southwest Airlines, The Chicago Bulls, Miami Heat, Truist Bank, Clemson Football, Northwestern Mutual, Bayer, West Point Academy and more. Jon is a graduate of Cornell University and holds a Masters in Teaching from Emory University. He and his training/consulting company are passionate about developing positive leaders, organizations and teams.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Supreme Court sides with Bayer in a major Roundup ruling that could derail thousands of cancer-warning lawsuits and is drawing sharp criticism from MAHA activists - MAHA activist Vani Hari weighs in. DHS Secretary Markwayne Mullin clashes with House Democrats while detailing the administration's efforts to locate unaccompanied migrant children the federal government lost track of under President Biden. Denmark's center-left government considers a nationwide ban on broadcasting the Islamic call to prayer as it continues pursuing some of Europe's toughest immigration policies. A giraffe named Gracie remains on the loose in the Texas Hill Country as helicopters, drones and local authorities join the search and her owner offers a $5,000 reward.   Cozy Earth: Visit https://www.CozyEarth.com & Use code MEGYN for up to 20% off   Supersure Insurance: Upgrade your business insurance to a year-round SuperAgency at https://Supersure.com/Megyn Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Joe's Premium Subscription: www.standardgrain.comGrain Markets and Other Stuff Links —Apple PodcastsSpotifyTikTokYouTubeFutures and options trading involves risk of loss and is not suitable for everyone.

PODCAST/WEBSITE HEAD: Jamie Dimon succession race narrowsSTANDFIRST: Marianne Lake leaves bank as Doug Petno and Troy Rohrbaugh handed two of its largest divisionsDescription: The race to succeed JPMorgan Chase chief executive Jamie Dimon just got tighter, and the investment chief at insurance group Allianz is warning that the SpaceX bond sale signals markets are in ‘bubble territory'. Plus, the US Supreme Court shielded German pharmaceuticals group Bayer from thousands of lawsuits over its Roundup weedkiller.Mentioned in this podcast:Jamie Dimon promotes two potential successors at JPMorganSpaceX bond sale signals markets are in ‘bubble territory', warns Allianz CIOBayer wins crucial US Supreme Court ruling over Roundup weedkillerTell us your thoughts to enter a prize draw for a chance to win a pair of Bose QuietComfort Headphones worth £229. Take our survey: https://www.feedback.ft.com/c/a/6f9bJBvxsxaEBSIB5esBISOver 18s only. Find full T&Cs here Prize Draw winners' surnames and regions may be made available upon request, as required by the Advertising Standards Authority. If you do not want your information to be made available, please email Privacy.Officer@ft.com upon entry. For more information on your rights and how we use your data, please read our Privacy Policy.Want to get in touch? Email us at podcasts@ft.comNote: The FT does not use generative AI to voice its podcasts The FT News Briefing is produced by Victoria Craig, Sonja Hutson, Saffeya Ahmed, Katya Kumkova, and Fiona Symon. Our editor is Marc Filippino. Our show is mixed by Kelly Garry and Alex Higgins. Additional help from Gavin Kallmann, Michael Lello, Peter Barber and David da Silva. Our intern is Cole van Miltenburg. Our executive producer is Topher Forhecz. Flo Phillips is the FT's global head of audio. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Hohe Opferzahlen nach schweren Erdbeben in Venezuela befürchtet, Wichtiger US-Gerichtserfolg für Bayer im Glyphosat-Prozess, Bund und Länder einigen sich auf Finanzentlastung für Kommunen, In Danzig beraten internationale Geber über den Wiederaufbau der Ukraine, DFB-Team vor WM-Spiel gegen Ecuador, Extreme Hitze in Deutschland ist für viele eine große Herausforderung, Das Wetter

The people who are quietly checking out at work usually hide it well. They still show up. Something has just gone quiet. Martin Lesperance is a keynote speaker who delivers around 100 talks a year in more than 20 countries; his audiences started calling him the Simon Sinek of Quebec.In this conversation we get into:Why so many people have "quietly quit" & burning outThe four simple habits that pull a person, and a team, back to lifeWhy your real purpose was never the numbersAnd much more.This is less a talk about engagement than a story about choosing your attitude when you have every reason not to. If you have built something that works but does not feel like freedom, or you manage people who have gone quiet, you will leave with four things you can use today.

In dieser Episode spricht Erik Siekmann mit Simon Knittel von Jung von Matt Start über die radikale Verschlankung von Agenturprozessen und den gezielten Einsatz von Kommunikation zur Lösung gesellschaftlicher Probleme. Simon erklärt, warum klassische, monatelange Strategieprozesse für agile Unternehmen unbrauchbar sind und warum erfolgreiche Markenarbeit heute eine direkte C-Level-Beteiligung in ultrakurzen Sprints erfordert. Ein absolutes Highlight der Folge ist der tiefe Einblick in das vielfach ausgezeichnete Pro-Bono-Projekt „Recht gegen Rechts“: Erfahre, wie das Team durch die kreative Besetzung von Markenrechten (wie „VTR LND“) rechtsextremen Online-Handel blockiert, wie aus einem juristischen Eilverfahren gegen einen bekannten Neonazi ein historischer Sieg vor dem Oberlandesgericht wurde und wie die Plattform druck18.com über 30 NGOs im Kampf gegen den Hass vereint. Zudem gibt Simon einen exklusiven Ausblick auf seinen im Juli startenden Podcast „Brandbeschleuniger“. Über Simon Knittel: Simon Knittel ist einer der kreativen Köpfe hinter Jung von Matt Start, einer Unit der renommierten Agenturgruppe, die Markenprozesse für Startups und etablierte Corporates radikal vereinfacht und beschleunigt. Der gebürtige Bayer und Wahl-Berliner gilt in der Branche als krisenresistenter Vordenker, der die Grenzen klassischer Werbung aufbricht. Neben seiner kommerziellen Markenarbeit erlangte er vor allem durch seine bahnbrechenden, preisgekrönten Initiativen wie „Recht gegen Rechts“ und „Fashion Against Fascism“ (in Kooperation mit Zalando und Spreadshirt) internationale Aufmerksamkeit. Sein Ansatz zeigt eindrucksvoll, wie intelligente Kommunikation, strategischer Markenaufbau und deutsches Markenrecht als hocheffiziente Hebel eingesetzt werden können, um echten gesellschaftlichen Impact zu generieren. Hier geht es zum Anti-Nazi-Onlineshop: druck18.com Hier könnt ihr die Arbeit direkt unterstützen: Laut gegen Nazis auf Betterplace Hier geht es zum Connected Commerce Guide von Front Row. Der Marketing Transformation Podcast wird produziert von TLDR Studios.

“Everybody wants to have the numbers from other areas, but nobody really wants to share their own numbers.”

Check out the video version of this episode on HCPLive!Finerenone's expansion into non-diabetic kidney disease is prompting a broader rethink of how chronic kidney disease is measured, mechanistically understood, and treated across its many causes.On an episode of Don't Miss a Beat recorded at the 10th Annual Heart in Diabetes Meeting, hosts Stephen Greene, MD, meeting co-chair and heart failure specialist at Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation and cardiologist at Brigham and Women's Hospital, spoke with Katherine Tuttle, MD, professor of medicine at the University of Washington, about the phase 3 FIND-CKD trial and how it informs on the overall role of finerenone (Kerendia) in management of cardiovascular-kidney-metabolic syndrome.FIND-CKD showed finerenone slowed total estimated glomerular filtration rate (eGFR) slope by 0.7 mL/min/1.73 m² per year versus placebo, irrespective of diagnosis. Much of the discussion focused less on the number and more on why it counts as clinically meaningful.Drawing on CKD Prognosis Consortium data from hundreds of thousands of patients, Tuttle explained why eGFR slope reliably predicts kidney failure when a trial runs at least 2 years. CKD progresses rather than striking as a discrete event, so the field has moved toward endpoints measurable without waiting for organ failure or death.On safety, hyperkalemia occurred more often with finerenone than placebo, about 12% versus 3%, though fewer than 1% of patients discontinued. The framing was practical, with background SGLT2 inhibition expected to lower the risk.Mechanism anchors much of the conversation between Tuttle, Greene, and Vaduganathan.Tuttle highlighted how glomerular diseases, like IgA nephropathy, are immunologic disorders needing disease-specific therapy, yet all CKD converges on shared final common pathways of inflammation and fibrosis. Broad agents like finerenone target those pathways, making combination therapy the emerging model, pairing treatment of the inciting disease with control of progression.The group also discussed the field's trend toward precision nephrology. Protocol biopsies from the Kidney Precision Medicine Project showed only about half of patients labeled as diabetic CKD had classic diabetic nephropathy. A parallel to oncology followed, where deep phenotyping replaced uniform regimens, suggesting not every patient will need every drug.Tuttle positioned finerenone alongside renin-angiotensin system inhibitors and SGLT2 inhibitors as an emerging pillar for non-diabetic CKD, with GLP-1 receptor agonists and endothelin antagonists possibly to come. A pooled analysis of FIDELIO-DKD, FIGARO-DKD, and FIND-CKD showed roughly 30% reductions in kidney and cardiovascular outcomes and an 11% drop in all-cause mortality. The closing point held the cardiorenal patient often arrives through either specialty's door, making preservation of organ function and quality of life the shared aim.Relevant disclosures for Tuttle include Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Novo Nordisk, Roche, and Travere Therapeutics. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.References: Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. Published online June 4, 2026. doi:10.1056/NEJMoa2604625 Bayer. Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026. Bayer.com. Published June 2, 2026. Accessed June 21, 2026. https://www.bayer.com/en/us/news-stories/kerendia-in-non-diabetic-chronic-kidney-disease

Hitler och hans soldater var rejält påtända. Fredrik Sjöberg läser om drogernas roll i Tredje riket och funderar över litteratur som kan råda bot på bristande läsförståelse hos pojkar och unga män. Lyssna på alla avsnitt i Sveriges Radios app. ESSÄ: Detta är en text där skribenten reflekterar över ett ämne eller ett verk. Åsikter som uttrycks är skribentens egna. Essän sändes ursprungligen 2017-01-23.Ett återkommande katastroflarm i samhällsdebatten är den bristande läsförståelse som särskilt utmärker pojkar och yngre män. Problemet är nog ofta överdrivet, men det kan heller inte förnekas, och en mindre armé av pedagoger försöker därför tänka ut hur man ska få pojkarna att läsa lika många böcker som flickorna gör. Lätt är det inte. Eftersom ingen har lyckats fylla tomrummet efter Frans G Bengtsson, erbjuds inte mycket mer än torftiga deckare och biografiska hjälteepos om onaturligt rika män som har lyckats förlänga sin barndom genom att sparka boll.Och allt det där är nog bra, men kanske kräver pojkarnas nu rent epidemiska indolens ändå tyngre doningar, och då är det noga taget bara två typer av böcker som duger: sådana som handlar om Hitler, och sådana som handlar om droger. Bägge dessa ämnen har en förunderligt vitaliserande inverkan också på mycket trötta existenser – så låt oss ett ögonblick tala om den från tyska översatta fackboken Droger i Tredje riket, av Norman Ohler. En svårslagen kombination, en form av litterärt blandmissbruk som lovar att höja läsförståelsen både hos datorspelande hemmapojkar och tröga haschtomtar med större frisyr än förstånd.Redan här bör dock inflikas att Norman Ohler inte är någon muntergök, utan en djupt seriös arkivdykare med ambitionen att vara historiskt objektiv, och att hans bok av det skälet inte riktigt når upp till samma stilistiska nivå som den avlägset besläktade satiren Jägarna på Karinhall, Carl-Henning Wijkmarks debutroman från 1972 – en klassiker som förutom sin rollbesättning av råsupande nazister på kalas hemma hos morfinisten Hermann Göring, även har fördelen av att vara både rolig och djupsinnig samt, inte minst, pornografisk. Den kombinationen slår ingen.Hur som helst, Droger i Tredje riket utgår från tidigare svåråtkomliga dokument som speglar dels användningen av amfetamin inom Wehrmacht och Luftwaffe, dels omfattningen av det drogmissbruk som förvandlade führern själv till en darrande pundare utan större verklighetskontakt. Det är onekligen fascinerande läsning. Skrämmande också, med tanke på att kemisterna knappast har legat på latsidan sen dess och sannolikt kan förse nutidens makthavare och mördarmaskiner med ännu effektivare blandningar av uppiggande och avtrubbande preparat.Den tyska drogindustrin var tidigt världsledande. Opiater hade man sysslat med länge och redan i slutet av 1800-talet lanserade läkemedelsbolaget Bayer en medicin mot hosta och huvudvärk som kallades Heroin. Senare, under Weimarrepubliken, sköt produktionen av morfin och andra opiater i höjden. Bara under ett enda år – 1928 – förädlades närmare 200 ton opium, och vid det laget hade de tyska bolagen även lagt under sig hela 80 procent av världsmarknaden för kokain. Tonvis. Inte var man så noga med restriktioner heller; lagstiftningen hängde inte med i svängarna, så när nazisterna i början av 30-talet formerade sig för en attack mot den unga demokratin, fanns många missbrukare man kunde stigmatisera som depraverat slödder i den förment sunda, ariska staten. Hitler själv gällde för att vara en renlevnadsman, så nu skulle drogträsket saneras. Det gick inget vidare.Som så ofta var det sportfånarna som testade gränserna. Under Berlinolympiaden 1936 nåddes tidigare oanade resultat med hjälp av prestationshöjande medel. Dopning. Framför allt lyckades amerikanerna vinna tack vare en sorts amfetamin som hette Benzedrine. Det var fullt accepterat inom idrotten på den tiden, och tyskarna vill nu inte vara sämre. Redan året därpå hade man utvecklat en mångdubbelt starkare variant av metylamfetamin som kom att kallas Pervitin. Ett uppåttjack av guds nåde, renare och bättre än allt vad den fiktive drogfabrikören Walter White lyckas koka ihop i TV-serien Breaking Bad.Pervitin blev snabbt en folkdrog i Tredje riket. Medlet användes för att integrera simulanter och gnällspikar i arbetslivet, för att motverka depressioner, sjösjuka, klimakteriebesvär, hösnuva och allmän håglöshet. Koncentrationsförmågan stegrades, liksom sexualdriften, och inte behövde man sova så mycket heller, vilket naturligtvis öppnade för användning i det militära. En sovande soldat gör inte mycket nytta. Efter en lagom dos Pervitin kunde man kriga flera dygn i sträck. Dessutom försvann rädslan, andra hämningar också. När Wehrmacht väl hade gjort sin beställning låg produktionen på i runda slängar 800 000 Pervitintabletter – per dag.Amfetaminmissbruket är såklart inte hela förklaringen till de tyska framgångarna i början av kriget, men blixtanfallen i Polen och Frankrike låter sig åtminstone delvis begripas i ljuset av att åtskilliga soldater faktiskt var påtända. Även generalerna. Den ryktbare fältherren Erwin Rommel krossade allt motstånd på västfronten tack vare en för tjackpundaren typisk form av hänsynslös självöverskattning. Först långt senare, i höjd med Stalingrad, började drogbrukets nackdelar bli märkbara.Om allt detta berättar Norman Ohler i sin bok, men till historien hör också huvudpersonen själv, Adolf Hitler, och hans livläkare, sedermera langare, Theodor Morell. Att Hitler mot slutet av kriget behandlades med fullkomligt fantastiska mängder hormoner, steroider och mediciner av alla slag är sedan länge väl känt, men forskarna har hittills varit ovilliga att betrakta honom som narkoman. Snarare har bilden varit att Hitler hade ett pressande jobb, och därför gott kunde behöva lite speed för att komma i form, och att hans vegetariska diet påkallade diverse kosttillskott.Nu framträder en helt annan bild. Av Theodor Morells bevarade anteckningar framgår att han ordinerar allt starkare doser av narkotika, inte bara Pervitin. Särskilt efter attentatet i Varglyan, 20 juli 1944, när Hitler sånär dödades av Claus von Stauffenbergs portföljbomb, behövdes också alltmer smärtstillande, och lugnande. Morell petade i honom duktiga doser kokain, gärna i kombination med Eukodal, ett morfinliknande preparat som gavs intravenöst. Tidvis var patientens vener lika illa åtgångna som på en durkdriven heroinist. Framåt vintern det året, när kriget i praktiken redan var förlorat, var han mycket nära att sluta sina dagar genom en överdos.Hur det sedan gick vet alla. Det nya i Norman Ohlers historieskrivning är tanken att Hitler möjligen inte alls drabbades av Parkinson eller någon annan sjukdom som till sist förvandlade honom till ett kraftlöst vrak, utan att han istället, på vårkanten 1945, kort före självmordet i bunkern, huvudsakligen led av abstinens. Vid det laget hade nämligen de allierade bombat läkemedelsfabrikerna till grus och aska. Och langarens lager av droger var slut.Likt alla tyska författare är Ohler mycket noga med att inte förringa eller bortförklara Hitlers ansvar för krigets bestialiteter, och han befinner sig sålunda, litterärt sett, långt ifrån Frans G Bengtssons lediga legender om brutala hjältekonungar och flugsvampdrogade bärsärkar, så när allt kommer omkring är kanske den bristande läsförståelsen bland pojkar bäst avhjälpt genom att skolbiblioteken köper in klassuppsättningar av Röde Orm. Eller varför inte Jägarna på Karinhall. I alla händelser är Droger i Tredje riket, komplett med register och notapparat, en förnämlig bredvidläsningsbok.Fredrik Sjöberg, författare och biolog LitteraturNorman Ohler: ”Droger i tredje riket – det dopade blixtkriget” (Lind & co), översättning Henrik Lindberg.

Sermon delivered on the Fourth Sunday After Pentecost, 2026, at Harrisburg, Pennsylvania, by Rev. Tobias Bayer.  Epistle: Rom. 8:18–23  |  Gospel: Luke 5: 1–11

O Frederico Barreto da Syngenta e o Fábio Passos da Bayer falam sobre as inovações de biotecnologia que estão chegando no mercado.

In dieser Folge von „Schach für Kinder“ wird es sportlich und strategisch zugleich! Xenia Bayer nimmt euch mit in die Welt des Schachboxens – einer Sportart, die auf den ersten Blick völlig verrückt klingt. Wie passen ein ruhiges Schachbrett und ein harter Boxring zusammen? Das erwartet euch in dieser Episode:Die Geschichte: Erfahrt, wie die Robinson-Brüder in London und der Niederländer Iepe Rubingh diese außergewöhnliche Kombination erfunden haben (inspiriert durch einen Comic!). Die Regeln: 11 Runden, abwechselnd Schach und Boxen. Wie gewinnt man? Durch K.o. oder durch Schachmatt? Die mentale Herausforderung: Was passiert im Körper, wenn man mit hohem Puls vom Boxen direkt ans Schachbrett ... Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.

In dieser Folge von „Schach für Kinder“ wird es sportlich und strategisch zugleich! Xenia Bayer nimmt euch mit in die Welt des Schachboxens – einer Sportart, die auf den ersten Blick völlig verrückt klingt. Wie passen ein ruhiges Schachbrett und ein harter Boxring zusammen? Das erwartet euch in dieser Episode:Die Geschichte: Erfahrt, wie die Robinson-Brüder in London und der Niederländer Iepe Rubingh diese außergewöhnliche Kombination erfunden haben (inspiriert durch einen Comic!). Die Regeln: 11 Runden, abwechselnd Schach und Boxen. Wie gewinnt man? Durch K.o. oder durch Schachmatt? Die mentale Herausforderung: Was passiert im Körper, wenn man mit hohem Puls vom Boxen direkt ans Schachbrett wechselt? Profis erklären, wie man trotz Adrenalin einen kühlen Kopf bewahrt. Live-Feeling: Wir nehmen euch mit an den Ring zu einem spannenden Match zwischen Lars Rooch und Mazen Girke. Wer behält am Ende die Oberhand? Schon gewusst? Zum Schluss gibt es einen lustigen Fakt aus der Schachgeschichte: Warum wurden eigentlich Schachuhren eingeführt? (Kleiner Tipp: Es hat mit schlafenden Spielern zu tun!

In this episode Derek Champagne talks with NY Times best selling author Liane Davey. Liane has spent more than 25 years researching and advising teams on how to perform at their best. Known as the “teamwork doctor,” she works with teams from the frontlines to the boardroom, across industries and around the world, from Boston to Bangkok. Through her work with hundreds of teams, including 26 Global Fortune 500 companies (and counting), she has developed a practical, research-backed approach to solving the challenges that prevent teams from working effectively together.Liane is a New York Times bestselling author of You First: Inspire Your Team to Grow Up, Get Along, and Get Stuff Done and The Good Fight: Use Productive Conflict to Get Your Team and Organization Back on Track. She is a regular contributor to Harvard Business Review and a sought-after expert for media outlets including CNN, NPR, USA Today, The Globe & Mail, and Forbes. Her work focuses on increasing productivity, strengtheningengagement, developing leaders, and helping teams navigate conflict in healthier, more effective ways.Liane's clients have included Amazon, Walmart, TD Bank, RBC, AMD, MD Anderson, Google, Bayer, KPMG, Aviva, UNICEF, and SONY Interactive Entertainment. While she works across a wide range of industries, she customizes every conversation to reflect the realities of each audience.In Thoughtload, Liane tackles today's most pressing management challenges: over-burdened systems, burned-out teams, and plateauing results. However, contrary to conventional wisdom, Davey argues that the problem is not with out-sized workloads. The root cause of the madness sapping productivity in today's offices is our excessive thoughtload.Thoughtload is the cumulative and often overwhelming burden of increasing cognitive and emotional demands, worsened by decreasing physical and mental energy. In this brilliant, highly prescriptive guide, Davey lays out the steps for reducing thoughtload, so that managers and their teams feel more focused―and get more done.For free resources and to order a copy of Thoughtload visit: Thoughtload.comBusiness Leadership Series Intro and Outro music provided by Just Off Turner: https://music.apple.com/za/album/the-long-walk-back/268386576

Sermon delivered on the Sunday Within the Octave of the Sacred Heart, the Third Sunday After Pentecost, 2026, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer.  Epistle: 1 Peter 5, 6-11; Gospel: Luke 15, 1-10

Owen Ansah hat Geschichte geschrieben. 9,98 Sekunden über 100 Meter. Er ist der einzige Deutsche, der je unter die Zehn-Sekunden-Marke gelaufen ist. Und sein Trainer Sebastian Bayer hat das Ganze von der Couch aus verfolgt – frisch operiert, Schulter kaputt.In dieser Folge spricht Sebastian Bayer über den Lauf in Regensburg, über den langen Weg dahin – und warum er Owen und seine Athleten in den ersten Jahren absichtlich ausgebremst hat. Denn seine These ist eindeutig: Wer zu früh zu spezifisch trainiert, macht aus einem möglichen 10,05-Athleten einen 10,35-Athleten – für immer.Außerdem geht es um die Frage, die jeder Leistungssportler kennt: Was passiert im Kopf, wenn man an eine Schallmauer stößt?Sebastian Bayer ist ehemaliger Europameister im Weitsprung, mehrfacher Deutscher Meister und heute einer der gefragtesten Sprintcoaches in Deutschland. Er trainiert am Stützpunkt Mannheim und hat mit Owen Ansah und Lucas Ansah-Peprah die zwei schnellsten Sprinter der deutschen Geschichte aufgebaut.In dieser Folge: Wie Sebastian den 9,98-Lauf in Regensburg erlebt hat – und was die Daten sagen. Warum Griffkraft, Sprünge und Hütchenläufe wichtiger sind als 1080-Sprints. Fundament-Metapher: Kein Mensch redet beim Hausbau über das Velux-Fenster, wenn das Fundament noch nicht gegossen ist. Was 99 Prozent Wille mit einem Prozent Loslassen zu tun hat. Und warum Sebastian sagt, er selbst hat das damals nicht gut hinbekommen.Schneller auf den ersten Metern — das Rock'n'Roll-ModellDu trainierst, gibst alles — aber auf den ersten Metern kommst du nicht voran? Das ist manchmal kein Kraft- oder Konditionsproblem. Es ist ein Mechanikproblem.Nach dem Konzept von Dr. Tobias Alt habe ich Buch und Onlinekurs entwickelt: das Rock'n'Roll-Modell für effizientere Beschleunigung. Für Sprinter, Fußballer, Basketballer, Handballer.Launch kommt bald — trag dich jetzt in die Warteliste ein und sichere dir den günstigsten Preis:

Tyler talks with Bailey Stockdale about their $13M Series B announcement. — This episode is presented by Ambrook. — Links Leaf - https://withleaf.io Leaf's Series B - https://www.agnavigator.com/Article/2026/06/11/bayer-invests-in-ai-backbone-company-leafs-series-b-round/ 

In this Cloud Wars Special report, Bob Evans speaks with Jan Gilg about how AI is reshaping enterprise software and why the next phase of innovation will depend on trust, governance, business outcomes, and clean data. Gilg explains how SAP is positioning its Autonomous Suite as a foundation for the autonomous enterprise, combining ERP, business processes, and AI agents. Trust Powers Enterprise AI The Big Themes: Autonomous Enterprise Vision: Jan Gilg said Sapphire generated strong enthusiasm because customers finally heard a clear vision for enterprise AI. Rather than focusing solely on AI models or isolated features, SAP presented an integrated strategy built around the Autonomous Suite and Business AI. While consumer AI has dramatically improved personal productivity, enterprise leaders need AI that can help make critical business decisions and automate end-to-end processes. SAP's message resonated because it connected AI directly to business execution, positioning enterprise systems as the foundation for autonomous operations rather than treating AI as a standalone technology layer. AI Economics Matter: Another major topic was the cost of AI. Gilg noted that enterprises are becoming increasingly focused on transparency, consumption, and measurable outcomes. As AI usage expands, costs can grow rapidly, creating new concerns for business leaders. Customers want detailed visibility into which agents are being used, how resources are consumed, and whether the resulting business value justifies the expense. Gilg compared this need for transparency to a detailed telephone bill. Data Quality Determines Success: The interview concluded with examples demonstrating that AI success depends heavily on modernized systems and clean data. Gilg spoke of initiatives involving retailers such as H&M, where AI can improve customer experiences, fulfillment, and revenue generation. He also referenced work with Bayer and discussed ExxonMobil's modernization journey. These examples reinforced a key point: AI delivers the greatest value when built on standardized processes, strong master data, and simplified architectures. The Big Quote: “You have to lead with value. Yes, technology is exciting, but it does nothing if the customer doesn't see the outcome." More from Jan Gilg and SAP: Follow Jan Gilg on LinkedIn or learn more about Autonomous Suite. Visit Cloud Wars for more.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory. The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development. Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page.Episode Breakdown: 1:10 – PROCEED trial efficacy in patients with prior preventive failures 5:10 – Safety and tolerability findings for bocunebart 6:30 – Coadministration data with ubrogepant and clinical implications 8:30 – Neurology News Network  10:50 – Rationale for combining PACAP and CGRP-targeted therapies 13:40 – Key considerations for future phase 3 development The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer's Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Der Besenwagen segelt über den Mondsee. Tobias Bayer vom Team Alpecin-Premier Tech steht am Steuerrad und blickt aus dem Schiebedach nach vorn. Der WorldTour-Profi aus Österreich ist bereits seit 6 Jahren im Dienste der belgischen Equipe und hat mit dem vergangenen Giro d‘Italia bereits genauso viele Grand Tours in den Beinen. Die darunter längste Etappe war ein eigentlich kurzes Zeitfahren…

Der FC Bayern und Eintracht Frankfurt haben einen „Durchbruch“ beim Transferpoker um Nathaniel Brown erzielt – das berichtet die „Bild“-Zeitung. Bayer 04 Leverkusen hat die Ausstiegsklausel des 16 Jahre alten defensiven Mittelfeldspielers Kennet Eichhorn gezogen und ihn bis 2031 unter Vertrag genommen. In der neuen Folge „DONE DEALS – der Transfermarkt-Podcast“ sprechen die Hosts Fabian Knottnerus und Lennart Gens über die beiden Personalien. Hat Eichhorn mit dem Wechsel zur Werkself die richtige Entscheidung getroffen und ist Nathaniel Brown wirklich 60 Millionen Euro wert?

Wat zit er in De 7 vandaag?De industrie duwt de deur grotendeels dicht voor flexi-jobs. In principe kan het vanaf 1 juli, maar heel wat sectoren passen ervoor.Sofwarereus Oracle doet de beleggers schrikken met hoger dan verwachten investeringen, in AI natuurlijk. Onze expert volgde de kwartaalresultaten.Het Gentse biotechbedrijf Aphea.bio gaat met het Duitse concern Bayer bio-insecticiden ontwikkelen. De CEO legt uit hoe ze dat gaan doen.En vandaag begint het meest politiek beladen WK voetbal ooit. Of moeten we zeggen: het meest commerciële ooit? Of gaat nu toch stilaan het sportieve gaan primeren? Host: Bert Rymen Productie: Joris Vanderpoorten Volg vanmiddag om 12 uur de Marktenchat over de beursgang van SpaceX See omnystudio.com/listener for privacy information.

Sermon delivered on Trinity Sunday, the First Sunday After Pentecost, 2026, at Queen of All Saints Chapel, in Youngtown, Arizona, by Rev. Tobias Bayer. Epistle: Romans 11:33–36 | Gospel: St. Matthew 28:18–20

In this episode of Better Advertising with BTR Media, Destaney sits down with Ana Sviatschi, Director of Digital Commerce at Future Beauty Brands, to talk about what it really takes to grow in today's beauty and ecommerce landscape.Ana shares her journey from Unilever to Bayer to Future Beauty Brands, and breaks down why brands often chase the “next shiny thing” before fixing the basics. From content and catalog health to SKU economics, TikTok Shop, AI, and leadership alignment, this conversation gets into the unsexy but essential work that actually drives growth.Connect with Ana on Linkedin: https://www.linkedin.com/in/ana-laura-sviatschi/ Connect with Destaney on Linkedin: https://www.linkedin.com/in/destaney-wishon/

On this episode of The Agronomists, your host Lyndsey Smith is joined by Peter Johnson of RealAg and Troy Basaraba of Bayer to talk about fighting fusarium! From appropriate timing, to water volume choices, nozzle selection and angle, to ground speed, boom height and harvest management, there is lots of ground to cover on this... Read More

Renu had been to an excellent Bayer Apex meeting in Europe in the past, so was very happy to hear Apex was coming to us for its first Asia-Pacific outing! A wonderful prostate cancer Faculty headlined by Neal Shore, Dan George, Derya Tilki, Fred Saad, Amit Bahl, Tamim Niazi to name but a few, plus almost 200 delegates from across the APAC region. Your usual hosts Renu Eapen and Declan Murphy catch up with some of the speakers and bring you conference highlights.This is a Themed Podcast, supported by our Gold Partner, Bayer Pharmaceuticals.

Join our champion program: mark@themomentumcompany.comAttend a Thriving Leader event: https://thriving-leader-2026.lovable.app/Instagram: @the.momentum.companyLinkedIn: /momentum-companyIn this episode of The Intentional Agribusiness Leader, Mark sits down with Jacqueline Langlois, founder of Gen D Consulting, for a deep conversation about leadership, AI, generational change, and what it means to lead intentionally in a rapidly evolving world.Jacqueline defines intentional leadership through one powerful image:Be the thermostat—not the thermometer.A thermometer reacts to the environment around it.A thermostat sets the tone.That mindset becomes increasingly important as organizations navigate uncertainty, digital transformation, and the accelerating rise of artificial intelligence.Jacqueline's background spans global agriculture leadership roles with companies like Bayer, Corteva, and Monsanto before launching Gen D Consulting—where she now focuses on executive leadership development and organizational strategy.The “D” in Gen D stands for:Digital Generation.Because regardless of age, today's workforce is connected digitally—and that reality is changing how people communicate, collaborate, and lead.A major theme throughout the episode is this:AI can scale operations.Human intelligence scales leadership.Technology can automate systems, accelerate workflows, and improve efficiency. But the human side of leadership—communication, emotional intelligence, cultural awareness, influence, and trust—becomes even more valuable as automation increases.The conversation also dives into one of the biggest transitions leaders face:Moving from tactical execution into strategic leadership.The behaviors that help someone succeed early in their career—being the doer, the problem solver, the technical expert—often become the very things holding them back at the next level.Leadership requires a shift:From execution to influenceFrom individual contribution to connectionFrom control to empowermentAnd that shift is uncomfortable.Jacqueline explains how many leaders stay trapped in familiar behaviors because those behaviors feel safe—even when they no longer serve the role they're in today.The discussion also explores generational leadership and the opportunities organizations are missing by not fully leveraging younger talent.Rather than forcing younger generations to simply “wait their turn,” leaders have an opportunity to invite fresh thinking, encourage innovation, and create environments where new ideas can challenge outdated assumptions.Because the reality is:The pace of change is accelerating.And organizations that continue operating with “this is how we've always done it” thinking risk getting left behind.The conversation also touches on one of the most important leadership responsibilities in today's environment:Upskilling people.As AI and automation reshape industries, leaders must think intentionally about how to help teams adapt, grow, and build new capabilities—not through fear, but through curiosity and development.The episode closes with a reminder that intentional leadership isn't about having all the answers.It's about creating clarity, staying adaptable, and being willing to step into discomfort in order to grow.Because in times of uncertainty, people don't need leaders who simply react to the room.They need leaders willing to set the temperature.Listen if you are:Navigating AI and digital transformation in your businessLeading teams through uncertainty or rapid changeTransitioning from tactical work into senior leadershipInterested in generational leadership and workforce developmentWanting to become a more intentional, adaptable leaderRESOURCES MENTIONEDJacqueline is the founder of Gen D Consulting, where she helps organizations develop leaders who can thrive in a rapidly changing, AI-driven world.As a special resource for listeners, Jacqueline is offering a complimentary Human Intelligence Self-Assessment designed to help leaders identify their strongest leadership capabilities and uncover their greatest growth opportunities.Access the assessment here:https://gendconsulting.com/resources#hi-assessmentUPCOMING LEADERSHIP EXPERIENCEIn July 2026, Jacqueline will host the Italy Leadership Summit, a unique leadership experience that brings together food, culture, and leadership development in one of the world's most influential agricultural regions.The summit is built around a simple idea:Leadership, like food, reflects the intention behind it.Participants will engage with local producers, explore centuries-old food systems, and gain fresh perspective on leadership through conversations centered on craftsmanship, purpose, connection, and human intelligence.Learn more about the Italy Leadership Summit:https://www.gendconsulting.com/italy-leadership-summitCONNECT WITH JACQUELINEWebsite: https://www.gendconsulting.com/Human Intelligence Self-Assessment: https://gendconsulting.com/resources#hi-assessmentItaly Leadership Summit: https://www.gendconsulting.com/italy-leadership-summitLinkedIn: https://www.linkedin.com/in/jacquelinelanglois/Gen D Consulting LinkedIn: https://www.linkedin.com/company/gen-d-consulting/Instagram: https://www.instagram.com/gendconsulting/X: https://x.com/GenDConsulting

How does Bayer R&D turn startup ideas into real-world impact? Learn how our research & development hubs drive future agricultural & healthcare innovations.   In this episode of Around the Farm, Dr. Ruth Shah, Head of Bayer Co.Lab Berlin, and Karl Collins, Director of Open Innovation Europe for Bayer Crop Science, join Tom and Andy to discuss how Bayer collaborates with startups to accelerate innovation across agriculture and healthcare. Learn how Bayer's global network of innovation hubs connects entrepreneurs, researchers, investors, and industry experts to bring new technologies to market faster. The conversation explores AI, open innovation, startup partnerships, soil health, regenerative agriculture, drug discovery, and the role innovation ecosystems play in solving some of the world's biggest challenges. Plus, hear examples of groundbreaking technologies emerging from Bayer Co.Lab and LifeHub and how they could shape the future of farming and medicine.

Mit Carles Martinez hat Bayer Leverkusen am Donnerstag einen hierzulande völlig unbekannten Trainer vorgestellt, der zuletzt dreieinhalb Jahre beim FC Toulouse gearbeitet hat. Sein Wirken dort lassen wir von unserem Frankreich-Korrespondenten Lucas Roignant beleuchten, außerdem geht der Blick ein weiteres Mal zum DFB-Team nach Chicago vor der Generalprobe gegen die USA.

Dr. Aly-Khan Lalani and Dr. Chris Wallis dive into the latest bladder cancer breakthroughs, starting with crucial long-term updates from the landmark EV-302 trial. They share encouraging survival data for patients, while exploring which treatments work best if the cancer eventually progresses. The doctors also discuss the future of localized disease, reviewing strategies from the POTOMAC and SAKK trials. By highlighting a range of advanced monitoring tools, they map out how modern care is helping patients safely avoid major surgery while maintaining excellent disease control.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering  immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved  counseling. The doctors finish the conversation by highlighting a promising new combination of repurposed drugs that is offering renewed hope to young patients fighting Renal Medullary Carcinoma.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial. Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

In this episode of Mind the Meds, Erica Marini, PharmD, highlights information from the European Stroke Organization Conference include encouraging data on asundexian(Bayer), a factor XIa inhibitor showing reduced recurrent ischemic stroke risk without increased bleeding, as well as positive results from three trials of tirofiban in acute ischemic stroke settings. On the multiple sclerosis (MS) front, Marini covers the FDA approval of ocrelizumab (Ocrevus; Genentech) for pediatric relapsing-remitting MS in children 10 and older, a new study supporting early use of high-efficacy agents in pediatric MS, and 2 Lancet publications on ocrelizumab — one examining higher weight-adjusted dosing (which did not improve disability progression) and one confirming benefit in a broader primary progressive MS population. She also briefly discusses PADOVA (NCT04777331), a phase 2b trial of prasinezumab in early Parkinson's disease, which failed to meet its primary end point.The bulk of the episode is a discussion with guest Millad Sobhanian, PharmD, BCPS, clinical pharmacy specialist in neurology at the University of Maryland, focused on Alzheimer disease. They cover dextromethorphan/bupropion (Auvelity; Axsome Therapeutics), newly approved in April 2026 for agitation associated with Alzheimer dementia. Sobhanian walks through key safety considerations—including additive NMDA antagonism if combined with memantine, cardiovascular risks from the bupropion component, and the ever-present black box warning on antipsychotics in dementia patients—while both note that the efficacy data, though statistically significant, shows modest clinical effect sizes compared to the threshold for meaningful within-patient change.The conversation then turns to lecanemab's subcutaneous initiation formulation (Leqembi Iqlik; Eisai, Biogen), whose FDA decision has been delayed to about August 2026 as regulators seek more data on bioavailability and ARIA monitoring in the at-home setting. Sobhanian shares his real-world perspective on anti-amyloid therapy, describing a patient population that is typically early-stage, high-functioning, and has a mean age of about 60 to 70 years, and emphasizing the pharmacist's role in expectation-setting around the modest but potentially cumulative slowing of cognitive decline. The episode closes with a thorough discussion of the April 2026 Cochrane review on amyloid-targeting monoclonal antibodies, which both Marini and Sobhanian find overly broad in its conclusions. They note limitations such as the inclusion of withdrawn agents like aducanumab (Aduhelm; Biogen), heterogeneous inclusion criteria across trials, and an 18-month study horizon that may be too short to capture the full benefit suggested by longer-term open-label extension data.Key Takeaways:1. New options for Alzheimer's agitation exist, but fit carefully into the treatment algorithm. Dextromethorphan/bupropion offers a novel NMDA-based mechanism for treating agitation in Alzheimer dementia, but its clinical effect size is modest, and it carries meaningful safety considerations—particularly around the bupropion component in elderly patients. Like all pharmacologic options in this space, it remains a later-line choice after nonpharmacologic interventions have been exhausted, and medication reconciliation is critical given its interaction potential with memantine and CYP2D6 inhibitors.2. Anti-amyloid therapies are imperfect but not ready to be written off. The April 2026 Cochrane review drew significant attention with its conclusion that anti-amyloid monoclonal antibodies produce only trivial cognitive benefits, but its findings are limited by the inclusion of older, withdrawn agents, heterogeneous trial populations, and an 18-month time horizon that may be too short to capture the full trajectory of benefit.3. The pharmacist's role in anti-amyloid therapy goes well beyond dispensing. As illustrated by Sobhanian's practice at the University of Maryland, clinical pharmacists embedded in neurology clinics play a critical role in patient selection, expectation-setting, ARIA counseling, and informed decision-making for patients considering anti-amyloid therapy—a complex, high-stakes treatment decision that these patients and their caregivers should never be navigating alone.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über Infineons historischen Rekord, die Disruptionsangst bei den Börsenbetreibern und warum die Börsenrallye in 2 Wochen abrupt enden könnte. Außerdem geht es um Nvidia, Hewlett Packard Enterprise, Broadcom, Applied Materials, Lumentum, Coherent, Qualcomm, ON Semiconductor, Lattice Semiconductor, Alphabet, Amazon, Microsoft, CoreWeave, Nebius, Salesforce, ServiceNow, Intuit, Workday, The Trade Desk, Palo Alto Networks, GitLab, Ulta Beauty, Infineon, Suss Microtec, Siemens, SAP, Bayer, Deutsche Börse, Cboe Global Markets, CME Group, Nasdaq, CrowdStrike, C3.ai, Five Below, Macy's, Medtronic, Rent the Runway, Inditex, Micron Technology, SK Hynix, AT&S, Ibiden, Unimicron, ING, Spotify, Amundi FTSE All World GDP-Weighted (WKN: ETF345). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Zephyr Teachout uses the question of organic integrity to explore a larger political problem: what happens when concentrated private power reshapes public rules while staying mostly within the law? Starting with the pressure on Real Organic to join forces with industrial organic against Bayer and Syngenta, she and Dave unpack corruption, anti-monopoly politics, regenerative agriculture, decentralization, and why any movement that gives up its leverage too early risks losing the very thing it set out to defend. https://realorganicproject.org/zephyr-teachout-organic-deal-with-devil The Real Organic Podcast is hosted by Dave Chapman and Linley Dixon, engineered by Brandon StCyr, and edited and produced by Jenny Prince. The Real Organic Project is a farmer-led movement working towards certifying 1,000 farms across the United States. Our add-on food label distinguishes soil-grown fruits and vegetables from hydroponically-raised produce, and pasture-raised meat, milk, and eggs from products harvested from animals in horrific confinement (CAFOs - confined animal feeding operations). To find a Real Organic farm near you, please visit: https://www.realorganicproject.org/directory We believe that the organic standards, with their focus on soil health, biodiversity, and animal welfare were written as they should be, but that the current lack of enforcement of those standards is jeopardizing the ability for small farms who adhere to the law to stay in business. The lack of enforcement is also jeopardizing the overall health of the customers who support the organic movement; customers who are not getting what they pay for at market but still paying a premium price. And the lack of enforcement is jeopardizing the very cycles (water, air, nutrients) that Earth relies upon to provide us all with a place to live, by pushing extractive, chemical agriculture to the forefront. To read our weekly newsletter and get firsthand news about what's happening with organic food, farming and policy, please subscribe here: https://www.realorganicproject.org/email/

Die DFB-Elf gewinnt mit 4:0 gegen Finnland. Lennart Karl und Deniz Undav machen dabei Werbung in eigener Sache. Bayer Leverkusen droht, wegen der Entlassung von Arne Slot in Liverpool, die Absage eines Wunschkandidaten.

The question is no longer whether brands should work with influencers. It's about how brands can leverage culturally relevant influencers as part of an integrated digital ecosystem that drives brand impact while building trust, brand equity and advocacy, all while staying compliant within industry regulations. Healthcare brands face some of the toughest such regulations, which is why this sector is so helpful to examine in this regard. That is why the counsel offered on this podcast from Real Chemistry's Erin Bittner, president of integrated communications, and Bayer's Courtney Ambrosi, director of consumer integrated marketing strategy, women's healthcare, is so valuable. During this conversation, the two discuss why cultural relevance and authenticity matter more than reach. They provide a blueprint for integration in a digital ecosystem. Help in measuring both the hard and soft value of influencer marketing is provided. And they make a compelling case for why compliance is a catalyst, not a constraint, for stronger influencer partnerships. If you want to learn how to work with influencers in a manner that will drive deeper credibility, connection and business impact, you've found the right podcast. PRWeek.comTheme music provided by TRIPLE SCOOP MUSICJaymes - First One Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Todd Arnedt, PhD, professor of psychiatry and neurology at Michigan Medicine-University of Michigan, joins the podcast to discuss the recently published American Academy of Sleep Medicine clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Arnedt explains the rationale behind formal recommendations for concurrent use of cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, particularly as combination treatment becomes increasingly common in clinical practice. The conversation reviews the evidence supporting CBT-I as the preferred foundational treatment approach, where combination therapy may offer advantages over pharmacotherapy alone, and how clinicians should think about factors such as symptom burden, treatment goals, access to CBT-I, and patient preference when selecting treatment strategies. Arnedt also outlines ongoing research gaps involving sequential treatment approaches, medication classes, long-term outcomes, and personalized insomnia care. Looking for more Sleep Disorders discussion? Check out the NeurologyLive® Sleep Disorders clinical focus page.Episode Breakdown: 1:15 – Why formal insomnia combination treatment guidance was needed 2:45 – Defining concurrent CBT-I and pharmacotherapy approaches 4:35 – Evidence supporting CBT-I as foundational insomnia treatment   7:15 – Situations where combination therapy may improve patient outcomes 7:50 – Neurology News Network  10:20 – Patient-specific factors influencing insomnia treatment selection 12:30 – Barriers involving CBT-I access, cost, and real-world implementation 16:55 – Research gaps surrounding sequencing, long-term outcomes, and personalization The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease FDA Grants Priority Review to Bayer's Asundexian for Secondary Stroke Prevention Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Im Finale der Champions League will Kai Havertz mit Arsenal gegen PSG den nächsten Titel. Bayer Leverkusen hat zwei Trainer-Favoriten. Wer zuerst zusagt bekommt den Job und beim VfL Wolfsburg steht ein großer Umbruch an.

The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying to deploy AI in GMP manufacturing, that is not a technical problem. It is the problem.Steffen Kreye has seen it from both sides. As former upstream development lead at Bayer and now Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he brings an unusually grounded perspective on where AI in bioprocessing actually stands, what the next generation of scientists needs to be equipped with, and what industry can do right now to help close the gap.Key topics discussed:How soft skills like teamwork and self-motivation are becoming increasingly important for scientists, and strategies to foster them in education (02:47)The reality behind AI and machine learning in biotech today, including current limitations and the true state of industry adoption (05:48)Envisioning bioprocessing ten years from now: the potential of continuous manufacturing, digital twins, and automation, and the evolving diversity of bioprocesses (08:09)Practical ways industry professionals can support university education—from guest lectures to hands-on lab courses—and why it matters (10:09)Motivating students by connecting coursework to real industry roles and contributions (12:10)The importance of finding and following individual motivation in science careers (12:41)Reflections on moving from industry to academia: autonomy, challenges, and the satisfaction of seeing students grow into scientists (13:22)How strong collaboration between academia and industry leads to better innovation and prepares future scientists for success (15:53)Smart Insight: Most companies talking about AI in bioprocessing are still solving a more fundamental problem: getting their data into a state where AI could use it at all. The breakthrough will not come from the algorithm. It will come from the unglamorous, years-long work of making data accessible, harmonized, and meaningful across sites, systems, and GMP boundaries.Here are some other guests who touched on similar themes:Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.Connect with Steffen Kreye:LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreyeNext Step:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he trains engineers who step into industry ready to run a bioreactor, not just describe one. His argument is direct: hands-on lab competence is the one thing AI cannot replicate, and it is exactly what underfunding is quietly eroding.Topics discussed:Why Steffen Kreye left his lab head role at Bayer to become a professor and how his career evolved (03:54)The unique mission of universities of applied sciences and their close connection to industry needs (11:16)Challenges of delivering lab-based education, including funding and equipment constraints (12:32)Creative strategies for partnering with biotech companies to sustain practical lab courses (14:34)How reading student theses, partnerships, and conferences help Steffen Kreye and his colleagues stay current in a rapidly changing field (17:43)The impact of AI and digital tools on research, teaching methods, and student assessment (21:18)Why traditional theoretical projects are less relevant, and the growing importance of problem-solving and oral examinations (22:09)In Part 2, Steffen gives his unfiltered take on where AI in bioprocessing actually stands, which human capabilities are becoming harder to replace, and what a well-prepared bioprocess engineer will need to look like by 2035.Smart Insight: Once AI can produce a polished report from a well-structured prompt, the only assessment that still reveals genuine understanding is the one a student has to navigate in real time, without a tool to hide behind.Here are some other guests who touched on similar themes:Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.Connect with Steffen Kreye:LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreyeNext Step:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Welcome to this Agronomic Monday edition of RealAg Radio! Today on the show, host Lyndsey Smith is joined by Peter Johnson of RealAgriculture to talk about the return of stripe rust, nitrogen and red clover in wheat. Also on today’s show, Jason Sauchuk of Bayer joins to talk about how to adapt spraying plans when... Read More

Send us Fan Mail“I only fear the Lord. I don't think, and if you don't, if you have that, when I get in to be governor, you're going up against teachers unions, Monsanto with the farmers, and Bayer, these giants. And I don't care.“ — Mike LindellMike Lindell returns to provide a massive update on his run for Minnesota Governor. Bypassing the media and establishment uniparty, Mike lays out his vision for the state's future, including a highly detailed, 120-day moratorium plan to handle the mass volume of illegals. He breaks down how he will deport criminals, issue provisional visas with English literacy requirements, and put employers in jail for paying under the table.Problem-Focused Timestamps & Moments of Gold 00:00:35 - David Pasqualone and Mike Lindell discuss the "Trifecta of Corruption" in Minnesota 00:04:23 - The Governor Run Update: Dividing Minnesota into 67 Senate districts for a grassroots sweep 00:05:50 - Facing the GOP Convention: Why Mike refuses to drop out for the establishment 00:06:40 - The 12-million-person marketing plan that no other candidate possesses 00:36:05 - The Illegal Crisis: Mike's detailed plan to deal with the mass volume of illegals 00:40:40 - Step 1: Immediate deportation of illegals with gross misdemeanors and felonies 00:41:53 - Step 2: The 120-Day Moratorium and the "Provisional Visa" with mandatory fingerprinting and English literacy tests 00:43:42 - Step 3: Mandatory six-month jail sentences for employers caught hiring illegals without provisional visasGuest Links & ResourcesSupport the Campaign: Visit MikeLindellGov.com to get involved. MyPillow Promo: Visit MyPillow.com and use code REMARKABLE to get free shipping and 50% off new mattresses! Support the showTHE NOT-SO-FINE-PRINT DISCLAIMER: While we are very thankful for all of our guests, please understand that we do not necessarily share or endorse the same beliefs, worldviews, or positions that they may hold. We respectfully agree to disagree in some areas, and thank God for the blessing and privilege of free will.For more Remarkable Episodes, Inspiration, and Motivation, please visit https://davidpasqualone.com/remarkable-people-podcast/ now!

Vance sits down with data engineer Rob Long — self-described as scoring near zero on the agreeableness scale — to dig into what professional AI use actually looks like. Rob walks through his work at Bayer building "Sales Companion," an iOS app that lets sales agronomists dump field notes, photos, and voice memos after customer visits, then uses an AI agronomy agent to surface product recommendations and flag crop disease issues the salesperson might have missed. It's a grounded, unglamorous look at how enterprise AI actually gets built and deployed.The conversation ranges widely, from the local optima problem (why hill-climbing strategies trap you on foothills instead of mountains) to how AI has turbocharged both of their understanding of history — Greek empires, Byzantine splits, the hard fork of the Protestant Reformation. Rob also makes a sharp case that English is simply the next layer of abstraction above high-level programming languages, the same way C replaced assembly — and that most "software engineers" are quietly becoming software engineering leads managing agents instead of writing code.As Bitcoin joins the conversation, Rob explains that his view is simple — figure out how to get paid in it, and stack what you can. He and Vance also trade takes on AI surveillance fears, driverless cars, the cost of keeping underperforming employees, and the surprisingly good lesson hiding inside every embarrassing work story.https://Articulate.Ventures/IBC/https://LegacyInterviews.com/

Sermon delivered on the Sunday Within the Octave of the Ascension, 2026, at Queen of All Saints Mission, in Richmond, Texas, by Rev. Tobias Bayer. pistle: 1 Peter 4, 7-11. Gospel: John 15, 26-27; 16, 1-4.